Norharmane

Norharmane (norharman, 9H-pyrido[3,4-b]indole, beta-carboline; CAS 244-63-3) is the unsubstituted parent compound of the beta-carboline alkaloid family, a tricyclic indole-pyridine heterocycle formed endogenously in mammalian tissues by Pictet-Spengler condensation of tryptamine with formaldehyde and present exogenously in tobacco smoke, cooked meats and fish, coffee brews, alcoholic beverages, and extracts of the ethnobotanical plant Peganum harmala. The compound is a multi-target neuroactive alkaloid whose principal characterized activities include reversible inhibition of monoamine oxidase A (Ki approximately 1.2 micromolar) and monoamine oxidase B (Ki approximately 1.12 micromolar), inverse agonism at the benzodiazepine binding site of the GABA-A receptor, high-affinity binding to imidazoline I2B receptors, weak dopamine reuptake inhibition (IC50 approximately 3,040 nanomolar at the dopamine transporter), inhibition of indoleamine 2,3-dioxygenase (Ki approximately 0.12 millimolar) and tryptophan 2,3-dioxygenase (Ki approximately 0.29 millimolar), weak serotonin 5-HT2B and 5-HT2C receptor affinity, and inhibition of steroidogenic cytochrome P450 enzymes CYP11 and CYP17. Plasma norharmane concentrations in nonsmoking adults are approximately 17 to 20 picograms per milliliter at baseline; concentrations rise sharply to approximately 177 picograms per milliliter within minutes of cigarette smoking and decline to near-basal levels within one hour. Cerebrospinal fluid levels of norharmane are significantly elevated in patients with Parkinson disease compared to controls, and plasma elevations have been documented in chronic alcoholism and essential tremor, raising the question of whether the compound functions as an endogenous neurotoxin, a compensatory neuroprotective signal, or both, depending on concentration and chronicity of exposure.

Preclinical pharmacology spans multiple domains. In rodent behavioral models, norharmane produces dose-dependent antidepressant-like effects in the forced swim test at intraperitoneal doses of 2.5 to 10 mg/kg, with the effect blocked by the benzodiazepine antagonist flumazenil, implicating benzodiazepine receptor mechanisms. Anxiolytic-like effects have been demonstrated in zebrafish and rodent models. Conversely, repeated subcutaneous administration (3 to 10 mg/kg in the published literature for five days) in C57BL/6 mice produces motoric impairment, glial fibrillary acidic protein upregulation, fluoro-jade-positive neurodegeneration, and sustained motor deficits two weeks after the last dose, without cognitive impairment. The structural resemblance of norharmane to the dopaminergic neurotoxin MPTP and its capacity to generate N-methylated carbolinium ions in vivo have sustained the hypothesis that chronic beta-carboline exposure contributes to the etiology of Parkinson disease. Anticancer activity has been characterized in vitro, with cytotoxicity against HeLa and BGC-823 cell lines at IC50 approximately 5 micrograms per milliliter, G2/M cell cycle arrest, and apoptosis induction. Antimicrobial activity includes quorum-sensing inhibition in Pseudomonas aeruginosa and moderate antibacterial and antifungal effects. Comutagenic activity, principally through cytochrome P450 inhibition rather than direct DNA intercalation, has been documented with multiple chemical carcinogens.

The compound is metabolized predominantly by hepatic CYP1A2 and CYP1A1 to 6-hydroxy-beta-carboline (the principal metabolite) and by CYP2E1 to the N(2)-oxide, with minor contributions from CYP2D6, CYP2C19, and CYP2E1. Oral bioavailability in humans is estimated at approximately 8 percent. No therapeutic indication has been approved by any regulatory authority. Norharmane is available as a research-grade chemical from multiple suppliers at greater than 98 percent purity and serves as the foundational scaffold for medicinal chemistry programs targeting beta-carboline derivatives for neurodegenerative, psychiatric, oncologic, and antimicrobial applications. This monograph reviews the chemistry, endogenous and exogenous sources, multi-target receptor pharmacology, pharmacokinetics, preclinical evidence across neurotoxicity and neuroprotection paradigms, anticancer and antimicrobial activity, the clinical biomarker evidence in Parkinson disease and essential tremor, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event and safety signals including mutagenicity, and a comparative assessment of five structurally related beta-carboline alkaloids (harman, harmine, harmaline, 9-methyl-beta-carboline, and tryptoline) against norharmane on five competency standards.